MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC) announced today that it has submitted documentation and a complete response to substantively address the issues raised by the US Food and Drug Administration (FDA) in connection with the Company’s plans to initiate a Phase I/II multicenter study using embryonic stem (ES) cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD). In November 2009, ACT filed an Investigational New Drug (IND) Application to commence treating patients. ACT believes the design of its product and the choice of SMD, from a safety standpoint, represents an ideal cellular product to gain early experience and knowledge about ES cell safety.
